Pacific Shuanglin Bio-pharmacy Co

Pacific Shuanglin Bio-pharmacy Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Pacific Shuanglin Bio-pharmacy Co (000403.SZ) as of Oct 29, 2026 is -131.04 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -26.69 % — a change of 390.97% (lower).

FCF Conversion

-131.04 %

YoY

390.97%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Pacific Shuanglin Bio-pharmacy Co is 2025 -131.04 % . FCF Conversion Rate (FCF/EBITDA) of Pacific Shuanglin Bio-pharmacy Co was 2024 -26.69 % . It decreases by 390.97% lower compared to the previous year.

The Pacific Shuanglin Bio-pharmacy Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
102.04 CNY
Jan 1, 2019
93.32 CNY
Jan 1, 2020
83.17 CNY
Jan 1, 2021
20.98 CNY
Jan 1, 2022
24.79 CNY
Jan 1, 2023
49.29 CNY
Jan 1, 2024
-26.69 CNY
Jan 1, 2025
-131.04 CNY
The Pacific Shuanglin Bio-pharmacy Co FCF Conversion history
YEARFCF ConversionYoY
-131.04 %+390.97%
-26.69 %-154.14%
49.29 %+98.81%
24.79 %+18.16%
20.98 %-74.77%
83.17 %-10.88%
93.32 %-8.55%
102.04 %-129.08%
-350.90 %+394.49%
-70.96 %-604.21%
14.07 %+187.87%
4.89 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pacific Shuanglin Bio-pharmacy Co Stock analysis

What does Pacific Shuanglin Bio-pharmacy Co do? Pacific Shuanglin Bio-pharmacy Co., Ltd. generates revenue through the production and marketing of pharmaceutical products including human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin. The company targets domestic healthcare providers and hospitals within China as its primary customers. Its core business focuses on supplying essential therapeutic products for medical treatment and patient care. The firm operates exclusively within the domestic Chinese market without international expansion. The company's product portfolio consists of specialized immunoglobulins and blood-derived therapeutic agents. These products serve critical medical needs such as immune support, infection prevention, and treatment of specific diseases. Domestic hospitals and healthcare institutions are the primary buyers of these pharmaceutical solutions. The business model relies on consistent domestic demand for these specialized medical products. Pacific Shuanglin Bio-pharmacy's revenue streams are derived from the sale of its core pharmaceutical products to Chinese healthcare facilities. The domestic market remains the sole operational focus, with no indication of international sales or additional product lines beyond those listed. The company's workforce of 2,093 full-time employees supports this focused production and distribution model. Pacific Shuanglin Bio-pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pacific Shuanglin Bio-pharmacy Co stock

FCF Conversion Rate (FCF/EBITDA) of Pacific Shuanglin Bio-pharmacy Co is -131.04 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Pacific Shuanglin Bio-pharmacy Co changed from -26.69 % to -131.04 %, representing a 390.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Pacific Shuanglin Bio-pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Pacific Shuanglin Bio-pharmacy Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Pacific Shuanglin Bio-pharmacy Co

All Key Metrics — Pacific Shuanglin Bio-pharmacy Co